Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel
NASDAQ:NRIX

Nurix Therapeutics Q2 2026 Earnings Report

Nurix Therapeutics logo
$16.95 -0.03 (-0.18%)
Closing price 04:00 PM Eastern
Extended Trading
$17.07 +0.12 (+0.68%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nurix Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.73
Beat/Miss
N/A
One Year Ago EPS
N/A

Nurix Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$15.95 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nurix Therapeutics Announcement Details

Quarter
Q2 2026
Date
7/9/2026
Time
Before Market Opens
Conference Call Date
Wednesday, July 8, 2026
Conference Call Time
9:30AM ET

Conference Call Resources

Nurix Therapeutics Earnings Headlines

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in ...
June 11 at 11:38 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nurix-therapeutics-to-report-updated-phase-1a-b-results-for-btk-degrader-bexobrutideg-highlighting-durable-responses-in-relapsed-refractory-cll-sll-and-promising-activity-in-earlier-lines-of-therapy-1036241949
Nurix Therapeutics Deal With Roche Is Worth Betting On
June 11 at 9:48 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4914204-nurix-therapeutics-deal-with-roche-is-worth-betting-on
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analyst Lance Ippolito says the real opportunity is elsewhere. He's identified 5 dirt-cheap stocks at the forefront of this mega-IPO, including a space ticker that Goldman Sachs, BlackRock, and Morgan Stanley are all buying, a rare resource miner Elon's entire empire depends on, and the chip supplier Starlink satellites can't function without. Access his free SpaceX Investing Blackbook before IPO day arrives.tc pixel
June 12 at 1:00 AM  |  InvestPub (Ad)
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
June 11 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/11/3310331/0/en/nurix-therapeutics-to-report-updated-phase-1a-b-results-for-btk-degrader-bexobrutideg-highlighting-durable-responses-in-relapsed-refractory-cll-sll-and-promising-activity-in-earlie.html
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NRIX) and Incyte (INCY)
June 10 at 10:34 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NRIX/pressreleases/2384703/analysts-have-conflicting-sentiments-on-these-healthcare-companies-nurix-therapeutics-nrix-and-incyte-incy/
Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics
June 9 at 7:28 PM  |  msn.comhttps://www.msn.com/en-us/health/other/roche-enters-cancer-drug-deal-worth-up-to-23-billion-with-nurix-therapeutics/ar-AA257rvs
See More Nurix Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nurix Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your email.

About Nurix Therapeutics

Nurix Therapeutics (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development. Among these are targeted protein degraders designed to eliminate key signaling proteins implicated in B-cell malignancies and inflammatory disorders. Nurix advances both proprietary and partnered assets, leveraging its Maestro™ platform to generate novel therapeutic candidates that reflect its expertise in medicinal chemistry, structural biology and protein degradation technologies.

Founded in 2015 and headquartered in San Francisco, California, Nurix collaborates with leading pharmaceutical companies to accelerate discovery and development. These strategic alliances complement the company’s in-house capabilities, enabling the translation of early research into clinical candidates and enhancing its capacity to address diseases that have proved difficult to treat with conventional approaches.

Under the leadership of Chief Executive Officer Christalynn Sayers and an experienced management team, Nurix Therapeutics continues to advance its proprietary pipeline through clinical trials and regulatory engagements. The company remains committed to pioneering new modalities that selectively dismantle disease drivers, with the goal of delivering transformative medicines to patients worldwide.

View Nurix Therapeutics Profile
Earnings Tools